Johnson & Johnson Considers Divesting Orthopedics Unit, Potential Valuation Exceeds $200 Billion

Deep News02-20

According to informed sources, Johnson & Johnson is preparing to sell its orthopedics business unit, which it had planned to spin off, and major private equity firms have begun showing interest in the potential transaction.

The DePuy Synthes business could be valued at over $200 billion in a sale. Johnson & Johnson has started compiling relevant documents and financial materials for DePuy Synthes to facilitate meetings with potential buyers in the coming weeks. It is reported that several large private equity companies are considering a consortium bid for the business.

DePuy Synthes manufactures devices for hip and knee replacements and reported sales of $93 billion last year. The business may also attract interest from competing medical device companies.

Discussions are currently in early stages, and there is no guarantee that a sale will ultimately be completed.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment